Epicutaneous Aeroallergen Exposure Induces Systemic TH2 Immunity That Predisposes to Allergic Nasal Responses
Overview
Authors
Affiliations
Background: Atopic individuals are predisposed to mounting vigorous T(H)2-type immune responses to environmental allergens. The skin is often the first organ that manifests allergic disease and may provide an early entry point for antigen sensitization.
Objective: We sought to determine whether epicutaneous exposure to the aeroallergen Aspergillus fumigatus induces nasal allergic responses. Furthermore, we aimed to examine the mechanism involved.
Methods: Wild-type and signal transducer and activator of transcription 6 (STAT6)-deficient mice were exposed to epicutaneous A fumigatus and control antigen ovalbumin. Nasal inflammation and responsiveness to methacholine were monitored.
Results: Exposure to epicutaneous A fumigatus antigen induced a marked atopic dermatitis-like phenotype in a manner significantly more efficient than epicutaneous ovalbumin. A single A fumigatus intranasal challenge induced clinical nasal responses and hyperresponsiveness to methacholine in the nose as manifested by nasal symptoms, accompanied by allergic airway and nasal inflammation. Mechanistic analysis using gene-targeted mice revealed that the clinical nasal responses and hyperresponsiveness were STAT6-dependent. Although STAT6 was required for changes in nasal responses, it was not required for epicutaneous pathology except eosinophilia.
Conclusion: Epicutaneous exposure to the aeroallergen A fumigatus potently primes for STAT6-dependent nasal responses. These results draw attention to the cooperative interaction between the nasal tract and skin.
Clinical Implications: The skin is a potent site for antigen sensitization in the development of experimental allergic rhinitis.
Examining the Role of Type 2 Inflammation in Eosinophilic Esophagitis.
Chehade M, Falk G, Aceves S, Lee J, Mehta V, Leung J Gastro Hep Adv. 2024; 1(5):720-732.
PMID: 39131849 PMC: 11307682. DOI: 10.1016/j.gastha.2022.05.004.
Scientific journey to the first FDA-approved drug for eosinophilic esophagitis.
Rothenberg M J Allergy Clin Immunol. 2022; 150(6):1325-1332.
PMID: 36209816 PMC: 9742179. DOI: 10.1016/j.jaci.2022.09.027.
Herman K, Yoshida T, Hughson A, Grier A, Gill S, Beck L Front Immunol. 2022; 13:817427.
PMID: 35265075 PMC: 8900519. DOI: 10.3389/fimmu.2022.817427.
Longitudinal atopic dermatitis endotypes: An atopic march paradigm that includes Black children.
Biagini J, Kroner J, Kyzy A, Gonzales A, He H, Stevens M J Allergy Clin Immunol. 2021; 149(5):1702-1710.e4.
PMID: 34673050 PMC: 9275099. DOI: 10.1016/j.jaci.2021.09.036.
Innate Type 2 Response to in a Murine Model of Atopic Dermatitis-like Skin Inflammation.
Park A, Lee E, Park H, Park M, Lee J, Song K J Korean Med Sci. 2021; 36(40):e261.
PMID: 34664800 PMC: 8524237. DOI: 10.3346/jkms.2021.36.e261.